在一项具有实验验证的泛癌研究中，ADAMDEC1预测预后和免疫疗法反应
ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation.
摘要(中文译文)
背景：ADAMDEC1（一种去整合素和金属蛋白酶结构域样蛋白decysin-1）与免疫紊乱和癌症相关，但其在泛癌中的作用仍不明确。方法：我们利用癌症基因组图谱（TCGA）、基因型-组织表达计划（GTEx）、基因表达综合数据库（GEO）以及乳腺癌国际联盟分子分类数据库（METABRIC）对ADAMDEC1的表达、预后、免疫浸润和治疗反应进行了分析。检测了单细胞RNA测序（scRNA-seq）和基因组改变。基因集富集分析（GSEA）评估了相关通路。免疫组织化学（IHC）在食管癌（ESCA）组织芯片（n=48）中验证了ADAMDEC1。使用肿瘤免疫功能障碍与排斥（TIDE）及独立队列预测免疫治疗反应。结果：ADAMDEC1在多种癌症中表达失调，其预后意义具有背景依赖性：高表达与低级别胶质瘤（LGG）和葡萄膜黑色素瘤（UVM）的不良生存相关，但在卵巢癌（OV）和皮肤黑色素瘤（SKCM）中与更好的结局相关。单细胞分析揭示了一种二分性：在UVM中，ADAMDEC1主要存在于肿瘤相关巨噬细胞中；在SKCM中，它广泛表达于恶性细胞、免疫细胞和基质细胞。DNA甲基化在20种癌症中与表达呈负相关。ADAMDEC1与免疫浸润及免疫调节基因相关，包括程序性细胞死亡蛋白1（PD-1）。在ESCA中，ADAMDEC1在转移灶中升高，并与PD-1呈正相关。ADAMDEC1对免疫治疗反应的预测能力与传统生物标志物相当。结论：ADAMDEC1是一种背景依赖性的免疫调节因子，其预后方向由细胞来源决定，支持将其作为精准肿瘤学中的治疗靶点和生物标志物进行进一步研究。
Abstract
BACKGROUND: ADAMDEC1 (a disintegrin and metalloproteinase domain-like protein decysin-1) is linked to immune disorders and cancers, but its pan-cancer role remains unclear. METHODS: We analyzed ADAMDEC1 using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) for expression, prognosis, immune infiltration, and therapy response. Single-cell RNA sequencing (scRNA-seq) and genomic alterations were examined. Gene set enrichment analysis (GSEA) assessed pathways. Immunohistochemistry (IHC) validated ADAMDEC1 in esophageal cancer (ESCA) tissue microarray (n = 48). Immunotherapy response was predicted using Tumor Immune Dysfunction and Exclusion (TIDE) and independent cohorts. RESULTS: ADAMDEC1 was dysregulated across cancers with context-dependent prognosis: high expression correlated with poor survival in lower-grade glioma (LGG) and uveal melanoma (UVM), but better outcomes in ovarian cancer (OV) and skin cutaneous melanoma (SKCM). Single-cell analysis revealed a dichotomy: in UVM, ADAMDEC1 was mainly in tumor-associated macrophages; in SKCM, it was broadly expressed across malignant, immune, and stromal cells. DNA methylation inversely correlated with expression in 20 cancers. ADAMDEC1 linked to immune infiltration and immunomodulatory genes including programmed cell death protein 1 (PD-1). In ESCA, ADAMDEC1 was elevated in metastasis and positively correlated with PD-1. ADAMDEC1 predicted immunotherapy response comparably to conventional biomarkers. CONCLUSIONS: ADAMDEC1 is a context-dependent immune regulator with prognostic direction determined by cellular origin, supporting its investigation as a therapeutic target and biomarker in precision oncology.
如何引用
AMA
Shuchen Lin, Hui Cong, Zhen Li, Lihua Zhang, Xinmiao Yang, Jie Fu. ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation.. Discover oncology. 2026; doi:10.1007/s12672-026-04977-3.
APA
Shuchen Lin, Hui Cong, Zhen Li, Lihua Zhang, Xinmiao Yang, Jie Fu (2026). ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation.. Discover oncology. https://doi.org/10.1007/s12672-026-04977-3
GB/T 7714
Shuchen Lin, Hui Cong, Zhen Li, Lihua Zhang, Xinmiao Yang, Jie Fu. ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation.[J]. Discover oncology, 2026 doi:10.1007/s12672-026-04977-3.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出